A study to evaluate the prebiotic effect of Manuka Honey with Cyclopower (Trademark) capsules in healthy subjects.
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the prebiotic effect of Manuka Honey with Cyclopower (Trademark) capsules in healthy subjects.
The New Zealand Institute for Plant and Food Research
20 participants
Sep 17, 2015
Interventional
Conditions
Summary
The primary objective of this study is to evaluate the prebiotic effect of Manuka Honey with CycloPower (Trademark) in healthy volunteers after oral administration for 21 days. Prebiotics are defined as non-digestible substances that pass undigested through the upper part of the gastrointestinal tract and stimulate the growth and/or activity of health promoting bacteria that colonize the large bowel. The study is a randomized, double-blind, placebo-controlled, cross-over study to evaluate the prebiotic effect of Manuka Honey with CycloPower (Trademark) capsules in healthy subjects. Eligible subjects will consume 1600 mg (2 capsules twice per day) of Manuka Honey with Cyclopower or a matching placebo with food. The study will consist of 2 treatment periods (TP1 and TP2) of 21 days with an intervening washout period of 14 days. Following successful screening, eligible subjects will be randomized (Day 0) to receive either the active treatment or matching placebo during TP1. After 2 weeks washout, during which they will take no study treatment, subjects will receive the other treatment during TP2. Subjects will be given sufficient supplies for 7 days of outpatient treatment after which (Days 7, 14, 21) subjects will return to the clinic for tolerability and dosing compliance assessments. Blood samples will be obtained at the beginning and the end of each treatment to assess general metabolism and blood counts. Subjects will be provided with containers to collect faecal samples on days 0, 1, 3, 7, 14 and 21 of each treatment which should be returned to the clinic for analysis.
Eligibility
Inclusion Criteria8
- Healthy subjects age 18 to 45 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs at screening.
- Subjects must be non-smoking (no use of tobacco products in the previous 3 months).
- Subjects must have a body mass index (BMI) within the range of 18 to 29 kg/m2 inclusive at screening.
- Subjects of childbearing potential must be using an acceptable method of contraception for the duration of the study.
- Subjects must be able to communicate well with the investigator, to
- understand and comply with the requirements of the study and
- understand and sign the written informed consent.
- Subjects must be willing not to use any other probiotic or prebiotic supplements for the duration of this study. Note: The eating of yoghurt / probiotic foods may continue during the study as long as there is no change in the product eaten or in the amount and frequency of ingestion.
Exclusion Criteria8
- A past medical history of clinically significant disease or abnormality.
- Known allergy to any bee products or Honey Cyclopower
- Known allergies or food intolerance to fibre-based products
- Use of any prescription drugs within 7 days prior to initial dosing in this study, other than occasional use of analgesics (less than 3 days in any 7-day period) and hormonal contraceptives
- Use of any recreational drugs in last 7 days prior to initial dosing in this study
- Significant illness within two (2) weeks prior to initial dosing.
- Dosing of a study drug in any clinical investigation within 30 days prior to initial dosing in this study.
- Pregnant and breast feeding women.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Manuka Honey with Cyclopower (Trademark) is a fine powder produced by combining (complexing) medical grade (MGO400+) Manuka Honey (45%) with alpha cyclodextrin (55%), a naturally occurring sugar molecule. The complexing process uses liquid honey and produces a fine powder which is presented in a hard shell capsule for oral administration. The primary objective of this study is to evaluate the prebiotic effect of (total dose of 1600 mg/day) Manuka Honey with CycloPower (Trademark) in healthy volunteers after oral administration for 21 days. Tolerability and safety data will also be reported. The study will consist of 2 treatment periods (TP1 and TP2) of 3 weeks with an intervening washout period of 2 weeks. After successful screening, eligible subjects will be randomized (Day 0) to receive either the active treatment or matching placebo during TP1. After 2 weeks washout during which they will take no study treatments, subjects will then receive the other treatment during TP2. Participants will be asked to take two 400 mg Manuka Cyclopower chewable tablets with food, twice per day for 3 weeks. During the course of the study participants will be asked to provide faecal samples at the following time points; on days 0, 1, 3, 7, 14 and 21 of each treatment to evaluate faecal bacterial populations and immune markers. Blood samples will be obtained at the beginning and the end of each treatment to assess general metabolism and blood counts. Participants are required to return all unused tablets at the end of the study and note and report when they have missed doses either by text, phone call or at the time of tablet return.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000857505